New Strong Sell Stocks for April 26th

Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating

Amphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year earnings growth

Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity

Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know

Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know

Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?

Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?

Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note

Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

New Strong Sell Stocks for March 18th

Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet

Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet

Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares

Amphastar Pharmaceuticals Inc Director Michael Zasloff Sells 12,500 Shares

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference